拜瑞妥吃多长时间？

(Rivaroxaban) is a new generation oral anticoagulant drug used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, prevent and treat deep vein thrombosis in adults, and treat pulmonary embolism. The advantages of Xarelto are very prominent. It can be used clinically to treat a variety of diseases and has fewer side effects. Patients can use it with confidence. Today we will learn more about how long to take Xarelto?

Xarelto (rivaroxaban) 10 mg can be taken with food or alone. Xarelto 15 mg or 20 mg tablets should be taken with food.

To prevent venous thrombosis in adults undergoing elective hip or knee replacement surgery:

The recommended dose is Xarelto (rivaroxaban) 10 mg orally once daily. If the wound has stopped bleeding, the first dose of medication should be between 6 and 10 hours after surgery. For patients undergoing major hip surgery, the recommended course of treatment is 35 days. For patients undergoing major knee surgery, the recommended course of treatment is 12 days. If a missed dose occurs, patients should take Xarelto immediately and continue taking the dose once daily the next day.

Treat DVT (venous thrombosis) and reduce the risk of acute DVT recurrence and PE:

The recommended dose for initial treatment of acute DVT is 15 mg twice daily for the first three weeks, followed by 20 mg once daily for maintenance treatment and to reduce the risk of recurrent DVT and PE.

For use in adult patients with non-valvular atrial fibrillation to reduce the risk of stroke and systemic embolism:

The recommended dose of Xarelto (rivaroxaban) is 20 mg once a day, which is also the maximum recommended dose. For patients with low body weight and elderly patients (>75 years old), doctors can use 15 mg once a day as appropriate based on the patient's condition.

The main clinical indications are: 1. For the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. 2. Indicated to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. 3. For use in adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism. The length of treatment with Xarelto (rivaroxaban) is determined by each patient's risk of VTE, i.e. by the type of orthopedic surgery the patient has undergone.

The above is the content of the medication duration of (rivaroxaban), I hope it can help you!

Recommended related hot articles: /newsDetail/76338.html